Supporting this hypothesis, ketamine was shown to decrease Iba1 immunoreactivity in the corpus callosum and pathological scores in a mouse model of MS (i.e., experimental autoimmune encephalomyelitis) (Wang et al., 2021). Here, AIF1 is linked to experimental autoimmune encephalomyelitis.